（编辑 任世碧） 证券日报网讯 11月14日晚间，九洲药业发布公告称，近日，公司全资子公司九洲生物医药（台州）有 限公司（原"浙江四维医药科技有限公司"）收到国家药品监督管理局核准签发的甲苯磺酸艾多沙班片的 《药品注册证书》。 ...

Market Overview - The medical services sector declined by 0.47% on November 14, with the digital human sector leading the drop [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Notable declines in individual stocks include: - Digital Human: closed at 17.28, down 4.85% with a trading volume of 80,400 shares and a turnover of 1.411 million [1] - Haoyuan Pharmaceutical: closed at 77.20, down 3.54% with a trading volume of 30,800 shares and a turnover of 2.4212 million [1] - Yinos: closed at 48.69, down 2.62% with a trading volume of 14,300 shares and a turnover of 7132.217 [1] - Other notable declines include Taige Pharmaceutical, MediX, and WuXi AppTec, all showing declines between 1.28% and 2.08% [1] Capital Flow - The medical services sector experienced a net outflow of 238 million yuan from institutional investors, while retail investors saw a net inflow of 181 million yuan [3] - Notable capital flows for specific stocks include: - Ruizhi Pharmaceutical: net inflow of 38.93 million yuan from institutional investors, but net outflows from retail and speculative investors [3] - Chengda Pharmaceutical: net inflow of 37.96 million yuan from institutional investors, with significant outflows from speculative investors [3] - Other stocks like Sanbo Brain Science and Jinyu Medical also showed varying net inflows and outflows among different investor types [3]

每经头条（nbdtoutiao）——展望"十五五"|专访财科院院长杨志勇：遏制地方政府新增隐性债务，债务 信息要透明，尽可能降低利息成本 （记者 曾健辉） 每经AI快讯，九洲药业（SH 603456，收盘价：21.46元）11月14日晚间发布公告称，近日，浙江九洲药 业股份有限公司全资子公司九洲生物医药（台州）有限公司收到国家药品监督管理局核准签发的甲苯磺 酸艾多沙班片的《药品注册证书》。产品名称为"甲苯磺酸艾多沙班"。 2024年1至12月份，九洲药业的营业收入构成为：化学原料药及中间体的生产及销售占比98.56%，其他 业务占比1.44%。 截至发稿，九洲药业市值为191亿元。 ...

近日，浙江九洲药业股份有限公司（以下简称"公司"）全资子公司九洲生 物医药（台州）有限公司（原"浙江四维医药科技有限公司"）收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的甲苯磺酸艾多沙班片的《药品 注册证书》，具体情况如下： 一、药品的基本情况 证券代码：603456 证券简称：九洲药业 公告编号：2025-067 浙江九洲药业股份有限公司 关于全资子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 生产单位：九洲生物医药（台州）有限公司 生产地址：浙江省台州市椒江区海门街道滨海路 59 号 药品名称：甲苯磺酸艾多沙班 剂型：片剂 规格：60mg、30mg 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 批准文号：国药准字 H20255929、国药准字 H20255930 批准文号有效期：至 2030 年 11 月 11 日 上市许可持有人：九洲生物医药（台州）有限公司 上市许可持有人地址：浙江省台州市椒江区海门街道滨海路 59 号 审批结论：根据《中华人民共和国药品管理法》 ...

Core Viewpoint - The company has received approval for the registration certificate of Tofacitinib Tosylate Tablets, enhancing its product pipeline and market competitiveness [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd., has obtained the drug registration certificate from the National Medical Products Administration for Tofacitinib Tosylate Tablets [1] - Tofacitinib Tosylate is an oral anticoagulant primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1] Group 2: Market Impact - The acquisition of the drug registration certificate will further enrich the company's product pipeline and help enhance its market competitiveness [1] - The recent approval is not expected to have a significant short-term impact on the company's performance [1] Group 3: Industry Characteristics - The production and sales of pharmaceutical products are influenced by market conditions, industry policies, and supply-demand relationships, which introduces a degree of uncertainty [1]

智通财经APP讯，九洲药业(603456.SH)发布公告，近日，公司全资子公司九洲生物医药(台州)有限公司 (原"浙江四维医药科技有限公司")收到国家药品监督管理局核准签发的甲苯磺酸艾多沙班片的《药品注 册证书》。 甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防非瓣膜性房颤患者的卒中及全身性栓塞，以及治 疗或预防深静脉血栓和肺栓塞。甲苯磺酸艾多沙班片最早由日本第一三共研发，于2011年4月在日本上 市。目前国内获得该药品注册证书的生产厂家为海南先声药业有限公司、山东新时代药业有限公司等。 ...

甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防非瓣膜性房颤患者的卒中及全身性栓塞，以及治 疗或预防深静脉血栓和肺栓塞。甲苯磺酸艾多沙班片最早由日本第一三共研发，于2011年4月在日本上 市。目前国内获得该药品注册证书的生产厂家为海南先声药业有限公司、山东新时代药业有限公司等。 九洲药业（603456）(603456.SH)发布公告，近日，公司全资子公司九洲生物医药(台州)有限公司(原"浙 江四维医药科技有限公司")收到国家药品监督管理局核准签发的甲苯磺酸艾多沙班片的《药品注册证 书》。 ...

截至发稿，葛兰累计任职时间10年293天，现任基金资产总规模435.44亿元，任职期间最佳基金回报 109.26%， 任职期间最差基金回报-35.13%。 资料显示，浙江九洲药业股份有限公司位于浙江省台州市椒江区外沙路99号，成立日期1998年7月13 日，上市日期2014年10月10日，公司主营业务涉及化学原料药及医药中间体的研发、生产与销售。主营 业务收入构成为：新药定制研发和生产服务(CDMO)79.81%，特色原料药及中间体18.22%，其他 1.96%。 从九洲药业十大流通股东角度 数据显示，中欧基金旗下1只基金位居九洲药业十大流通股东。中欧医疗健康混合A（003095）三季度 增持397.67万股，持有股数1740.3万股，占流通股的比例为1.96%。根据测算，今日浮盈赚取约1879.52 万元。连续4天上涨期间浮盈赚取1583.67万元。 中欧医疗健康混合A（003095）成立日期2016年9月29日，最新规模169.77亿。今年以来收益24.47%， 同类排名3925/8140；近一年收益13.31%，同类排名4906/8056；成立以来收益114.81%。 11月14日，九洲药业涨5.31% ...

Core Points - The ownership structure of Jiuzhou Pharmaceutical has changed, with Huaxuande no longer holding shares in Zhongbei Group and Taizhou Gede, leading to a new actual controller structure involving Huali Rong and Huaxiao Hui [2][3] - Jiuzhou Pharmaceutical reported a revenue of 4.16 billion yuan for the first three quarters of the year, reflecting a year-on-year growth of 4.92%, and a net profit of 748 million yuan, up 18.51% year-on-year [4] Group 1 - Huaxuande transferred 28.50% of Zhongbei Group's shares to Huali Rong and 14% to Huaxiao Hui, with total payments amounting to 61.815 million yuan [2] - Following the transfer, Huali Rong holds 22.17% and Huaxiao Hui holds 13.36% of Jiuzhou Pharmaceutical indirectly [2] - The market value of Jiuzhou Pharmaceutical shares held by Zhongbei Group and Taizhou Gede is estimated at approximately 24.76 billion yuan [2] Group 2 - Jiuzhou Pharmaceutical, established in July 1998, is a technology-driven CDMO enterprise focusing on small molecule drugs, peptide drugs, conjugated drugs, and small nucleic acid drugs [3] - Huaxuande, aged 82, stepped down as chairman in 2014, with his daughter Huali Rong succeeding him [3] - Huali Rong has held various leadership roles and was recently elected as the executive director and legal representative of Jiuzhou Pharmaceutical [3] Group 3 - Huaxuande and his family's wealth was ranked 338th on the Hurun Rich List in 2020 with 16 billion yuan, and they are currently ranked 2750th and 940th on the global and national rich lists, respectively [4] - As of November 13, Jiuzhou Pharmaceutical's stock price increased by 2.11% to 20.34 yuan per share, with a market capitalization of 18.091 billion yuan [4]

Core Viewpoint - The control of Jiuzhou Pharmaceutical has changed due to the transfer of shares from the aging actual controller, Hua Xuande, to his daughters, Hua Lirong and Hua Xiaohui, which will not affect the company's operational independence or business performance [2][4]. Group 1: Share Transfer Details - Hua Xuande transferred 42.50% of his shares in Zhongbei Group and 10.00% in Taizhou Gede to his daughters, with Hua Lirong receiving 28.50% and Hua Xiaohui 14% of Zhongbei Group, and each receiving 5% of Taizhou Gede [1]. - The total payment for the share transfer was 61.815 million yuan, with Hua Lirong paying 41.333 million yuan and Hua Xiaohui 20.482 million yuan [1]. - The estimated market value of the shares transferred, based on Jiuzhou Pharmaceutical's closing price of 19.88 yuan per share, is approximately 2.476 billion yuan [1]. Group 2: Company Background and Performance - Jiuzhou Pharmaceutical, established in July 1998, is a technology-driven CDMO enterprise focusing on small molecule chemical drugs, peptide drugs, conjugated drugs, and small nucleic acid drugs [4]. - The company reported a revenue of 4.16 billion yuan for the first three quarters of the year, representing a year-on-year growth of 4.92%, and a net profit of 748 million yuan, up 18.51% year-on-year [4]. - As of November 13, Jiuzhou Pharmaceutical's stock price increased by 2.11% to 20.34 yuan per share, with a market capitalization of 18.091 billion yuan [5].